Navigation Links
A product for the detection and characterization of brucellosis launched at University of Navarra
Date:3/26/2008

This release is available in Spanish.

Ignacio Lpez-Goi and David Garca, researchers of the Department of Microbiology and Parasitology of the University of Navarra, have launched a new product for the detection and characterization of the Brucella bacteria, which is the causative agent for brucellosis, also known as Mediterranean fever. Their product is a commercial analysis kit, sold under the brand name Bruce-ladder, and was developed in collaboration with Ingenasa, a Madrid-based business dedicated to applied biotechnology in the areas of animal and human health and food safety.

Bruce-ladder permits the identification and differentiation of the microorganism via the amplification of sequences of specific genes using the PCR (polymerase chain reaction) technique. In order to develop this product, these microbiologists of the School of Sciences analyzed the complete sequences of the genomes of various distinct species of Brucella, which permitted them to design a system capable of differentiating them in a single test, and in less than 24 hours.

The novelty of this techniques derives from the fact that is able to distinguish all the known species of Brucella, including vaccine lines and the isolated species present in marine mammals.

A more rapid and safe analysis

"Up to now, differentiation of Brucella was only performed in central laboratories, by means of complicated biochemical and serological techniques, handling the bacteria themselves, which involved a risk for the laboratory personnel. Now, with this new molecular test, the bacteria samples can be analyzed in a simpler and more rapid manner, without having to handle the bacteria directly", as the microbiologists of the University of Navarra explained. The kit has been tested by various leading laboratories in France, Belgium and Portugal, and has been approved by the National Brucellosis Reference Center, in Granada.

Brucellosis is an infectious disease which affects both livestock and persons. According to the World Health Organization, brucellosis is part of a group of diseases, which also includes rabies and anthrax, which are considered forgotten diseases, and are strongly related to poverty. The incidence of brucellosis is very high in Africa, Asia, the Middle East and Latin America, and it is a factor in the lack of economic progress and development in these areas of the world. This new kit will aid in its diagnosis, and will permit epidemiological studies which will help to control and eventually eradicate the disease.


'/>"/>

Contact: Garazi Andonegi
garazi@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. London Luxury Receives Asthma & Allergy Friendly(TM) Certification for Several of Its Bedding Products
2. Jopari Ramps Up Texas eBill Production With National and Regional Carriers and Medical Billing Technology Suppliers
3. NY-Area Paramedic Wins 2007 Francis X. Hursey Award for Heroic Use of QuikClot(R) Blood Clotting Product
4. Blue Cross Blue Shield of Michigan Pioneers Total Body PPO Product
5. Scripps Florida scientists develop a process to disrupt hepatitis C virion production
6. Mirion Technologies to Showcase New Product Offerings for the Nuclear Industry During 10th Annual China International Nuclear Industry Exhibition
7. National Religious Coalition Deeply Concerned by HHS Secretarys Disregard for Womens Reproductive Health
8. Schiff(R) Introduces New Supplement Products for Intestinal Health and Beauty Maintenance
9. Do bacterial combinations result in enhanced cytokine production? No!
10. Leading Health Groups Applaud Continued Efforts to Protect Public Health by Ending So-Called Theatrical Productions in Bars
11. Sergeants(R) Pet Care Products Acquires the Consumer Brand Division of Virbac Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... GA (PRWEB) , ... February 12, 2016 , ... ... relationship-marketing firm announced that nominations have closed for the ISE Southeast Awards 2016. ... will be announced at the ISE® Southeast Executive Forum and Awards Gala on ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO ... Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern ... Nevada Healthcare System. This will be the first Fisher House in Nevada, and ...
(Date:2/12/2016)... ... ... Erlanger Agency has announced a new partnership in its ongoing community involvement ... the fight against breast cancer, fundraising for a local woman named Carmen, who is ... is a loving single mother of two boys who also serves as caregiver for ...
(Date:2/12/2016)... Lakeland, FL (PRWEB) , ... February 12, 2016 , ... ... Coast Dental hygienist Suzan Sweeney, RDH, and dental assistant Terrell Moore shortly before 7 ... They joined dozens of dental professionals, donating their time and skills to help hundreds ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Drug Categories: Strategies for Health Plans and PBMs,” an upcoming Feb. 24 webinar ... affordability and access in big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... SAN JOSE, Calif. , Feb. 12, 2016  SI-BONE, Inc., ... Implant System ® ("iFuse"), a minimally invasive surgical (MIS) device ... announced that National Government Services, Inc. (NGS), the Medicare Administrative Contractor ... Illinois , Maine , ... Hampshire , New York , ...
(Date:2/12/2016)... SEOUL, South Korea , Feb. 12, 2016 ... today announced they will form a partnership to ... medicine in cancer. The goal of the collaboration ... with Macrogen,s high-throughput Next Generation Sequencing capabilities toward ... Laboratory Improvement Amendments (CLIA) of 1988 by the ...
(Date:2/12/2016)... 12, 2016  Apellis Pharmaceuticals, Inc., today ... million Series D preferred stock financing, co-led ... Capital Group and venBio Global Strategic Fund, ... IB Investment, and Epidarex Capital. The proceeds of ... advance clinical trials in the Company,s ongoing ...
Breaking Medicine Technology: